Creative Planning - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 254 filers reported holding CRISPR THERAPEUTICS AG in Q4 2019. The put-call ratio across all filers is 1.45 and the average weighting 0.5%.

Quarter-by-quarter ownership
Creative Planning ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$678,583
+30.7%
14,950
+61.7%
0.00%0.0%
Q2 2023$519,171
+22.2%
9,248
-1.6%
0.00%0.0%
Q1 2023$424,938
-11.4%
9,395
-20.3%
0.00%0.0%
Q4 2022$479,458
-38.8%
11,795
-1.5%
0.00%0.0%
Q3 2022$783,000
+15.1%
11,977
+7.1%
0.00%0.0%
Q2 2022$680,000
+5.4%
11,185
+8.8%
0.00%0.0%
Q1 2022$645,000
-13.1%
10,281
+5.0%
0.00%0.0%
Q4 2021$742,000
-45.5%
9,790
-19.6%
0.00%
-50.0%
Q3 2021$1,362,000
-10.7%
12,170
+29.1%
0.00%
-33.3%
Q2 2021$1,526,000
-6.2%
9,428
-29.4%
0.00%0.0%
Q1 2021$1,627,000
-10.3%
13,352
+12.7%
0.00%
-25.0%
Q4 2020$1,814,000
+107.3%
11,850
+13.3%
0.00%
+100.0%
Q3 2020$875,000
+182.3%
10,459
+147.9%
0.00%
+100.0%
Q2 2020$310,000
-41.7%
4,219
-66.3%
0.00%
-50.0%
Q1 2020$532,000
-44.0%
12,536
-19.7%
0.00%
-33.3%
Q4 2019$950,000
+61.3%
15,604
+8.5%
0.00%
+50.0%
Q3 2019$589,000
-16.2%
14,376
-3.7%
0.00%0.0%
Q2 2019$703,000
+27.1%
14,935
-3.6%
0.00%0.0%
Q1 2019$553,000
+30.7%
15,486
+4.7%
0.00%0.0%
Q4 2018$423,000
-39.2%
14,791
-12.8%
0.00%0.0%
Q3 2018$696,000
+186.4%
16,964
+63.6%
0.00%
+100.0%
Q4 2017$243,00010,3700.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q4 2019
NameSharesValueWeighting ↓
Gilfoyle Management LLC 150$6,37612.96%
Versant Venture Management, LLC 498,558$22,629,54812.03%
NEA Management Company, LLC 1,587,854$72,072,6935.57%
ARK Investment Management 7,163,118$325,133,9132.49%
Nikko Asset Management Americas, Inc. 3,465,470$157,263,0291.88%
Integral Health Asset Management, LLC 275,000$12,482,2501.73%
Merlin Capital, Inc 9,092$412,6861.54%
Del-Sette Capital Management, LLC 33,977$1,542,2161.52%
Green Alpha Advisors, LLC 34,880$1,583,2031.22%
Ikarian Capital, LLC 2,039$9,255,0211.11%
View complete list of CRISPR THERAPEUTICS AG shareholders